Table 1.
Baseline characteristics of patients by the adjudicated groups (n = 565)
| Patient characteristics | I | II | III | IV | V |
|---|---|---|---|---|---|
| At‐Risk | At‐Risk + Symptoms | HF‐PEF | HF‐REF | Controls | |
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| n | 108 | 44 | 170 | 152 | 91 |
| Male | 47 (44) | 36 (82) | 91 (54) | 114 (75) | 34 (37) |
| Age, median (25th–75th percentile) | 64 (57, 70) | 67 (63, 73) | 73 (63, 80) | 64 (57, 72) | 62 (53, 72) |
| Ethnicity | |||||
| Caucasian | 102(94) | 38(86) | 153(90) | 136(90) | 86(95) |
| Aboriginal | 2(5) | 5(3) | 4(3) | ||
| South Asian | 3 (3) | 2 (5) | 8 (5) | 7 (5) | 5 (6) |
| Other | 3 (3) | 2 (5) | 4 (2) | 5 (3) | |
| CCS Angina classification | |||||
| 0 | 107 (99) | 26(59) | 138 (81) | 121(80) | 91 (100) |
| ≥1 | 1 (1) | 9 (20) | 22 (13) | 23 (15) | |
| Not available | 9(21) | 10(6) | 8(5) | ||
| NYHA functional classification | |||||
| Class I | 115 (100) | 15 (34) | 42 (25) | 34 (22) | 91 (100) |
| Class II | 6 (14) | 82 (48) | 70 (46) | ||
| Class III | 2 (5) | 44 (26) | 44 (29) | ||
| Class IV | 3 (2) | ||||
| Not available | 21 (48) | 2 (1) | 1 (1) | ||
| Patient report history of HF | 0 (0) | 3 (7) | 165 (97) | 151 (99) | 0 (0) |
| Primary aetiology of HF | |||||
| Ischaemic | 3(4) | 43 (25) | 74 (49) | ||
| Non‐Ischaemic | 122 (72) | 77 (51) | |||
| Dilated NOS | 59 (35) | 52 (34) | |||
| Hypertensive | 4 (2) | 1 (1) | |||
| Myocarditis | 5 (3) | 2 (1) | |||
| Sarcoid | 1 (1) | 0 | |||
| Alcohol | 2 (1) | 5 (3) | |||
| Amyloid | 1 (1) | 1 (1) | |||
| Valvular | 5 (3) | 1 (1) | |||
| Other | 12 (7) | 7 (5) | |||
| Unknown | 33 (20) | 8 (5) | |||
| Medical comorbidity | |||||
| Atrial fibrillation | 17 (16) | 6 (14) | 84 (49) | 62 (41) | 3 (3) |
| Coronary artery disease | 5 (5) | 43 (98) | 63 (37) | 81 (53) | 0 (0) |
| Diabetes | 34 (32) | 14 (32) | 67 (39) | 57 (38) | 0 (0) |
| COPD | 10 (9) | 3 (7) | 36 (21) | 27 (18) | 1 (1) |
| Laboratory and other measurements | |||||
| Haemoglobin, g/dL, median (25th–75th percentile) | 144 (132, 151) | 148 (138, 153) | 134 (122, 145) | 139 (127, 149) | 144 (132, 150) |
| Creatinine, umol/L, median (25th–75th percentile) | 77 (69, 91) | 91 (76, 104) | 97 (76, 125) | 97 (83, 120) | 79 (65, 86) |
| eGFR, mL/min, median (25th–75th percentile) | 98 (73, 123) | 88 (69, 110) | 68 (44, 98) | 81 (58, 109) | 83 (70, 106) |
| BNP, pg/mL, median (25th–75th percentile) | 28 (15, 51) | 45 (22, 116) | 118 (59, 264) | 191 (79, 367) | 23 (13, 41) |
| NT‐proBNP, pg/mL, median (25th–75th percentile) | 59 (33, 129) | 160 (47, 323) | 561 (200, 1362) | 1032 (414, 2121) | 52 (27, 94) |
| Weight, kg, median (25th–75th percentile) | 89 (77, 101) | 87 (79, 100) | 89 (73, 101) | 88 (77, 102) | 74 (64, 84) |
| BMI, median (25th–75th percentile) | 31 (27, 35) | 28 (26, 33) | 30 (27, 35) | 29 (26, 33) | 26 (24, 30) |
BNP, B‐type natriuretic peptide; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HF‐PEF, heart failure with preserved ejection fraction; HF‐REF, heart failure with reduced ejection fraction; NOS; not otherwise specificed; NT‐proBNP, N terminal pro BNP; NYHA, New York Heart Association.
Values are n (%) unless otherwise stated. Medians are presented with (25th–75th percentile). Because of rounding, not all percentages equal 100. eGFR was calculated by the modified diet in renal disease formula.